General Announcement::GPL becomes the first company in India to receive regulatory approval for oral antiviral Favipiravir

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
20-Jun-2020 16:38:19
Status
New
Announcement Sub Title
GPL becomes the first company in India to receive regulatory approval for oral antiviral Favipiravir
Announcement Reference
SG200620OTHRPZAC
Submitted By (Co./ Ind. Name)
For Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Description (Please provide a detailed description of the event in the box below)
Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19

Attachments

SGX_PR_20062020.pdf
Total size =1164K